Proceedings from the fourth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Amy Goodrich, Dr Brad S Kahl, Ms Robin Klebig and Dr Jeff Sharman.
Introduction (00:00)
Clinical presentation of chronic lymphocytic leukemia (CLL) and biomarkers predictive of response (4:58)
Differences in clinical manifestation between CLL and small lymphocytic lymphoma; educating the asymptomatic patient about the benefits of watching and waiting (12:49)
Counseling patients with CLL about the risks and benefits of acalabrutinib/obinutuzumab (18:47)
Mechanism of action, side effects and optimal integration of novel BTK and Bcl-2 inhibitors for CLL (26:22)
Caring for patients on ibrutinib therapy; role of the oncology nurse in providing emotional and psychological support (36:56)
Communicating the significance of clinical trial participation to patients with CLL; results from the Phase III CLL14 trial assessing fixed-duration venetoclax/obinutuzumab as up-front therapy (46:17)
Optimal use of venetoclax for CLL; patient education about, monitoring for and management of tumor lysis syndrome (54:53)
Selection and duration of front-line therapy for patients with CLL (1:03:41)
Monitoring patients receiving venetoclax to prevent tumor lysis syndrome (1:15:07)
Emerging data with the use of BTK inhibitor therapy for patients with COVID-19 (1:19:45)
Podden och tillhörande omslagsbild på den här sidan tillhör Dr Neil Love. Innehållet i podden är skapat av Dr Neil Love och inte av, eller tillsammans med, Poddtoppen.